Want to join the conversation?
Pharmaceutical and chemical company $MRK posted 3Q15 GAAP earnings of $0.64 per share vs. $0.31 per share in 3Q14. During the quarter, the company advanced the clinical development program for KEYTRUDA, a drug approved by the FDA for the treatment of advanced melanoma and metastatic NSCLC.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.